Skip to content

Kura Oncology

US · KURA #3283 by market cap Listed 2015
6.91 -0.44 -5.99%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Price chart

Pre-market 7.15 -2.72%
After-hours 6.94 +0.43%
13.596.806.912026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on KURA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -39.0% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 14.2% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → E

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2849 U.S. stocks StockVane covers.

Last computed: 2026-11-21 14:27 UTC

Data coverage: 4 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability D+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 99.9% Better than 99%
Operating margin -449.9% Better than 4%
Net margin -412.9% Better than 4%
Return on equity -94.8% Better than 6%
Return on invested capital -95.2% Better than 2%
Momentum D

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -41.9% Better than 9%
6-month return -38.6% Better than 13%
12-month return (ex latest month) -11.7% Better than 21%
Distance below 52-week high 50.3% Better than 18%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.1x Better than 89%
Debt to assets 2.8% Better than 85%
Interest coverage -183.1x Better than 4%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 307.2% Better than 98%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -11.07%
1M -30.76%
3M -40.99%
6M -33.17%
YTD -33.49%
1Y -37.07%
3Y -27.64%
5Y -59.33%

Key statistics

Price & volume

Prev close
7.35
Open
7.13
Day range
6.89 - 7.37
Avg price
7.05
Volume
1.75M
Turnover
12.35M
Amplitude
6.53%
52-week range
6.75 - 13.90

Valuation

P/E
-2.17
P/E (TTM)
-2.09
P/B
35.44
EPS
-3.18
Net profit
-292.17M
Net assets
17.92M

Share structure

Market cap
634.88M
Float cap
524.32M
Shares out
91.88M
Float shares
75.88M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2015-11-05
52-week range 2% of range
6.75 13.90

50.3% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-8.46M net over the window

Short interest

Shares short
12.64M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Kura Oncology (KURA)?

Kura Oncology last traded at 6.91. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Kura Oncology's market cap?

About 634.88M.

What is the P/E ratio of Kura Oncology?

The trailing twelve-month P/E is -2.09. The Valuation tab shows it against the stock's own five-year range.

Does Kura Oncology pay a dividend?

Kura Oncology does not currently pay a regular dividend.

Is Kura Oncology a buy according to analysts?

The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 28.14, which implies 307.2% upside from the current price. This is not investment advice.

What is Kura Oncology's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Kura Oncology a E (Strong Sell). Below its 200-day average and near the bottom of the universe on momentum. Not investment advice.

Quote time 2026-11-20 20:02:29 · For reference only, not investment advice and not tailored to your situation.

Kura Oncology discussion 0 comments

Add a comment